评价经导管动脉栓塞（TAE）联合CT导引经皮经肝肿瘤射频消融术（CT-RFA）治疗肝血管瘤的临床疗效。

36例患者均经CT扫描及血管造影诊断，共46个肝血管瘤。其中5例经活检病理证实。患者先经导管动脉超液化碘油及明胶海绵超选择栓塞治疗，然后行CT-RFA治疗129例次。

治疗后3个月复查肝脏CT扫描，39个肝血管瘤完全坏死，46个瘤体积缩小（80.41±10.26）%，与治疗前相比，P<0.01。对4个有部分存活的血管瘤再次行CT-RFA治疗5次；6个月复查肝脏CT扫描，4个肿瘤完全坏死，肿瘤体积缩小（89.21±7.17）%，与治疗前相比，P<0.01。

经导管动脉栓塞联合CT导引经皮经肝肿瘤射频消融术治疗肝血管瘤可使肿瘤完全坏死，是治疗肝血管瘤一种安全有效的方法。

To evaluate the treatment efficacy of hepatic hemangioma by transcatheter arterial embolization(TAE), CT-guided percutaneous radiofrequency ablation of liver tumors(CT-RFA).

Thirty-six patients(a total of 46 hemangiomas) were confirmed by CT scan and angiography in the diagnosis of hepatic hemangioma, including 5 cases of biopsy confirmed hepatic hemangioma. Patients before transcatheter arterial lipiodol and gelatin sponge embolization treatment, then underwent CT-guided percutaneous radiofrequency ablation of liver tumors, 46 hemangiomas of line(CT-RFA) treatment of 129 times.

Three months later, 39 tumors showed complete tumor necrosis, tumor size decreased in 46 of (80.41±10.26)%, P<0.01. Some of the four surviving cancer had conducted a CT-RFA treatment of a total of five times. Six months later four showed complete tumor necrosis, tumor size decreased (89.21±7.17)%, t=3.54, P<0.01.

TAE combined CT-RFA treatment of hepatic hemangioma can complete tumor necrosis, hepatic hemangioma is a safe and effective treatment.